“Studies have indicated that GH deficiency may lead to increased myostatin levels, which is an atrophic factor, with dissociation in autocrine IGF-1 effects on muscles’ protein synthesis. These are pro-sarcopenic phenomena. In adults with human immunodeficiency virus (HIV), Adrian et al. evaluated the role of tesamorelin, a GH-releasing hormone analog, in muscle mass. The results showed that among those treated patients with a clinically significant decrease in the visceral adipose tissue, tesamorelin effectively increased the density and area of the skeletal muscles, which are all anti-sarcopenic actions. Table 2 summarizes the studies performed with medications in sarcopenic patients.”
Mellen, R. H., Girotto, O. S., Marques, E. B., Laurindo, L. F., Grippa, P. C., Mendes, C. G., Garcia, L. N. H., Bechara, M. D., Barbalho, S. M., Sinatora, R. V., Haber, J. F. D. S., Flato, U. A. P., Bueno, P. C. D. S., Detregiachi, C. R. P., & Quesada, K. (2023). Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review. Biomedicines, 11(1), 136. https://doi.org/10.3390/biomedicines11010136
 
National Institute of Health Research Link:
https://pubmed.ncbi.nlm.nih.gov/28617838/